You are here:Home-Chemical Inhibitors & Agonists-Cell Cycle/DNA Damage-ATM/ATR-M4344
M4344

Chemical Structure : M4344

CAS No.: 1613191-99-3

M4344 (VX-803, Gartisertib, VX803, M 4344)

Catalog No.: PC-72163Not For Human Use, Lab Use Only.

M4344 (VX-803, Gartisertib) is a highly potent, selective ATR inhibitor with Ki<0.15 nM.

Packing Price Stock Quantity
5 mg $188 In stock
10 mg $298 In stock
25 mg $478 In stock
50 mg Get quote
100 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

M4344 (VX-803, Gartisertib) is a highly potent, selective ATR inhibitor with Ki<0.15 nM.
M4344 (VX-803, Gartisertib) showed minimal inhibitory activity against unrelated kinases, with >100-fold selectivity for ATR over 308/312 kinases tested.
M4344 suppressed cancer cell proliferation at lower concentrations, similarly to BAY1895344 and was more potent than berzosertib (VX-970, M6620), ceralasertib, and VE-821.
M4344 (25 nM) strongly suppressed cell viability of prostate DU145 cancer cells in combination of CPT at nanomolar concentrations, M4344 (10 nM) blocked CPT-induced activation of CHK1, a main downstream effector of ATR.
M4344 kills cancer cells under replication stress (RepStress) and with NE genomic signatures by replication-mediated DNA damage.
M4344 synergizes with clinical TOP1 inhibitor (Exatecan), as well as a broad range of widely used clinical agents including etoposide, gemcitabine, cisplatin, and talazoparib.
M4344 is active in patient-derived tumor organoids and xenograft models.

Physicochemical Properties

M.Wt 541.564
Formula C25H29F2N9O3
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO (5.4 mg/mL)

Chemical Name/SMILES

2-amino-6-fluoro-N-(5-fluoro-4-(4-(4-(oxetan-3-yl)piperazine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide

References

1. Ukhyun Jo, et al. Mol Cancer Ther. 2021 Aug;20(8):1431-1441.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: